PMID- 23151512 OWN - NLM STAT- MEDLINE DCOM- 20130219 LR - 20211021 IS - 1091-6490 (Electronic) IS - 0027-8424 (Print) IS - 0027-8424 (Linking) VI - 109 IP - 48 DP - 2012 Nov 27 TI - Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. PG - 19757-62 LID - 10.1073/pnas.1218260109 [doi] AB - Chronic infection with hepatitis C virus (HCV) is an important cause of end stage liver disease worldwide. In the United States, most HCV-related disease is associated with genotype 1 infection, which remains difficult to treat. Drug and vaccine development was hampered by inability to culture patient isolates representing HCV genotypes 1-7 and subtypes; only a recombinant 2a genome (strain JFH1) spontaneously replicated in vitro. Recently, we identified three mutations F1464L/A1672S/D2979G (LSG) in the nonstructural (NS) proteins, essential for development of full-length HCV 2a (J6) and 2b (J8) culture systems in Huh7.5 cells. Here, we developed a highly efficient genotype 1a (strain TN) full-length culture system. We initially found that the LSG substitutions conferred viability to an intergenotypic recombinant composed of TN 5' untranslated region (5'UTR)-NS5A and JFH1 NS5B-3'UTR; recovered viruses acquired two adaptive mutations located in NS3 and NS4B. Introduction of these changes into a replication-deficient TN full-length genome, harboring LSG, permitted efficient HCV production. Additional identified NS4B and NS5B mutations fully adapted the TN full-length virus. Thus, a TN genome with 8 changes (designated TN cell-culture derived, TNcc) replicated efficiently and released infectious particles of approximately 5 log(10) focus-forming units per mL; passaged TNcc did not require additional changes. IFN-alpha and directly acting antivirals targeting the HCV protease, NS5A, and NS5B, each inhibited full-length TN infection dose-dependently. Given the unique importance of genotype 1 for pathogenesis, this infectious 1a culture system represents an important advance in HCV research. The approach used and the mutations identified might permit culture development for other HCV isolates, thus facilitating vaccine development and personalized treatment. FAU - Li, Yi-Ping AU - Li YP AD - Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, DK-2650 Hvidovre, Denmark. FAU - Ramirez, Santseharay AU - Ramirez S FAU - Jensen, Sanne B AU - Jensen SB FAU - Purcell, Robert H AU - Purcell RH FAU - Gottwein, Judith M AU - Gottwein JM FAU - Bukh, Jens AU - Bukh J LA - eng SI - GENBANK/JX993348 GR - Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Intramural PT - Research Support, Non-U.S. Gov't DEP - 20121114 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (3' Untranslated Regions) RN - 0 (NS3 protein, flavivirus) RN - 0 (NS4B protein, flavivirus) RN - 0 (Viral Nonstructural Proteins) RN - EC 3.4.21.- (Serine Endopeptidases) RN - EC 3.6.4.13 (RNA Helicases) SB - IM MH - 3' Untranslated Regions MH - Cell Line, Tumor MH - Genotype MH - Hepacivirus/*genetics/pathogenicity/physiology MH - Humans MH - Molecular Sequence Data MH - Mutation MH - RNA Helicases/genetics MH - Recombination, Genetic MH - Serine Endopeptidases/genetics MH - Viral Nonstructural Proteins/genetics MH - Virus Replication PMC - PMC3511766 COIS- The authors declare no conflict of interest. EDAT- 2012/11/16 06:00 MHDA- 2013/02/21 06:00 PMCR- 2012/11/14 CRDT- 2012/11/16 06:00 PHST- 2012/11/16 06:00 [entrez] PHST- 2012/11/16 06:00 [pubmed] PHST- 2013/02/21 06:00 [medline] PHST- 2012/11/14 00:00 [pmc-release] AID - 1218260109 [pii] AID - 201218260 [pii] AID - 10.1073/pnas.1218260109 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19757-62. doi: 10.1073/pnas.1218260109. Epub 2012 Nov 14.